Clinical presentation, outcome and prognostic factors in dogs with immune-mediated haemolytic anaemia: a retrospective single-centre study of 104 cases in Ireland (2002–2020)

Table 5 Variables assessed for association with survival in the univariable analysis. Variables with P value below 0.2 were included in the multivariate model are indicated with *. Variable with P value below 0.05 are indicated with **

Variable	Hazard ratio	95% CI	P value
Age	1.140	1.031–1.261	0.01*
Sex (male)	1.093	0.560–2.132	0.80
Body weight (< 10 kg, 10–25 kg, > 25)	1.758 1.848	0.803–3.848 0.767–4.446	0.16* 0.17*
Increased urea concentration	1.530	0.833–2.808	0.17*
Increased creatinine concentration	2.728	0.649–11.46	0.17*
Increased bilirubin concentration	2.204	1.049–4.632	0.04**
Increased cholesterol concentration	1.623	0.885–2.977	0.12*
Decreased albumin concentration	1.378	0.478–3.968	0.55
Haematocrit	0.962	0.919–1.008	0.11*
Reticulocytes	0.997	0.995–0.999	0.04**
Leucocytosis	0.996	0.979–1.014	0.69
Neutrophilia	0.992	0.969–1.014	0.47
Increased band neutrophils	0.911	0.498–1.665	0.76
Lymphopenia	1.725	0.925–3.218	0.09*
Monocytosis	0.744	0.407–1.360	0.34
Thrombocytopenia	1.928	1.027–3.618	0.04**
Severe thrombocytopenia	1.684	0.708–4.007	0.24
CHAOS score	1.453	1.176–1.796	0.001**
Receiving a blood transfusion	1.231	0.945–1.604	0.12*
Number of blood transfusion	1.289	0.877–1.893	0.19*
Second-line immunomodulator	1.688	0.861–3.308	0.13*
Third-line immunomodulator	1.793	0.752–4.272	0.19*
Use of azathioprine	1.170	0.633–2.162	0.62
Use of cyclosporine	1.437	0.674–3.064	0.35
Use of mycophenolate	1.470	0.676–3.196	0.33
Relapse	1.44	0.515–4.054	0.49

ISSN: 2046-0481